Fundraising FoxComplexa
Pittsburgh, US · Founded 2012 · Delaware corporation · 5 known investors
Find your way into Complexa
Sign up to see every warm intro you have to Complexa
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Complexa team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
JM
Joshua M. TarnoffExecutive
DJ
Diane JorkaskyChief Medical Officer
FO
Federica O'BrienChief Financial Officer
Board
IW
I. Wistar MorrisBoard director
KH
Kenji HaradaBoard director
MT
Miwa ToyodaBoard director
CM
Carter MeyerBoard director
HH
Hironori HozojiBoard director
HJ
H. Joseph ReiserBoard director
PG
Peter GrebowBoard director
Investors · 5
Andera Partnerslisted by Andera PartnersParis
How we know: Andera Partners's portfolio page · Not right? Tell us
New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M
How we know: board seat on SEC Form D · funding news · press coverage · Not right? Tell us
Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M
How we know: Pfizer Venture Investments's portfolio page · funding news · press coverage · Not right? Tell us
HBM Healthcare InvestmentsreportedZug
How we know: funding news · press coverage · Not right? Tell us
Scientific Health DevelopmentreportedDallas · $2M
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$72.3M disclosed across 6 rounds · 2014–2019
▶$11MraisedApr 2019 · 4 investors · PharmaceuticalsRule 506(b)
▶$11MraisedApr 2019 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Barbara DaltonDirector
- Francisco D. SalvaExecutive Officer, Director
- Kenji HaradaDirector
- I. Wistar MorrisDirector
- Gilles NobecourtDirector
- David MottDirector
- Sara M. NayeemDirector
- Bernardus N. MachielseDirector
- Offering amount
- $28M
- Amount sold
- $11M
- Proceeds to insiders
- $302K
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40.6MraisedJul 2017 · 28 investors · PharmaceuticalsRule 506(b)
▶$40.6MraisedJul 2017 · 28 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- I. Wistar MorrisDirector
- David MottDirector
- Diane JorkaskyExecutive Officer
- Sara NayeemDirector
- Kenji HaradaDirector
- Federica O'BrienExecutive Officer
- Gilles NobecourtDirector
- Barbara DaltonDirector
- Joshua M. TarnoffExecutive Officer, Director
- Offering amount
- $62.6M
- Amount sold
- $40.6M
- Sales commissions
- $1.8M
- Proceeds to insiders
- $1.5M
- Placement agents
- Wedbush Securities Inc.
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedNov 2016 · 4 investors · PharmaceuticalsRule 506(b)
▶$1MraisedNov 2016 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- H. Joseph ReiserDirector
- Kenji HaradaDirector
- Carter MeyerDirector
- Miwa ToyodaDirector
- Diane JorkaskyExecutive Officer
- Federica O'BrienExecutive Officer
- I. Wistar MorrisDirector
- Peter GrebowDirector
- Joshua M. TarnoffExecutive Officer, Director
- Offering amount
- $1.4M
- Amount sold
- $1M
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$950KraisedApr 2016 · 6 investors · PharmaceuticalsRule 506(b)
▶$950KraisedApr 2016 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- I. Wistar MorrisDirector
- Carter MeyerDirector
- Miwa ToyodaDirector
- Frederica O'BrienExecutive Officer
- Kenji HaradaDirector
- Joshua M. TarnoffExecutive Officer, Director
- Peter GrebowDirector
- H. Joseph ReiserDirector
- Diane JorkaskyExecutive Officer
- Offering amount
- $2M
- Amount sold
- $950K
- Proceeds to insiders
- $169K
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$4MraisedJun 2015 · 8 investors · PharmaceuticalsRule 506(b)
▶$4MraisedJun 2015 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joshua M. TarnoffExecutive Officer, Director
- I. Wistar MorrisDirector
- H. Joseph ReiserDirector
- Kenji HaradaDirector
- Miwa ToyodaDirector
- Diane JorkaskyExecutive Officer
- Federica O'BrienExecutive Officer
- Peter GrebowDirector
- Carter MeyerDirector
- Offering amount
- $5M
- Amount sold
- $4M
- Proceeds to insiders
- $500K
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$14.8MraisedJun 2014 · 28 investors · PharmaceuticalsRule 506(b)
▶$14.8MraisedJun 2014 · 28 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Peter GrebowDirector
- Joshua M. TarnoffExecutive Officer, Director
- Hironori HozojiDirector
- H. Joseph ReiserDirector
- I. Wistar MorrisDirector
- Kenji HaradaDirector
- Carter MeyerDirector
- Offering amount
- $14.8M
- Amount sold
- $14.8M
- Minimum investment
- $10.3K
- Sales commissions
- $240K
- Proceeds to insiders
- $1.4M
- Placement agents
- Middlebury Securities, LLC
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Complexa's investors?
- Complexa's investors include Andera Partners, New Enterprise Associates (NEA), Pfizer Venture Investments, HBM Healthcare Investments, Scientific Health Development.
- How much funding has Complexa raised?
- Complexa has disclosed $72.3M raised across 6 rounds.
- Where is Complexa headquartered?
- Complexa is headquartered in Pittsburgh, US.